Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft standard: determination of chromatographic purity by… — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-004/3
Series
Public comment period
Version
1.0
Published
30 Jun 2023
Last reviewed
30 Jun 2023
Next review
30 Jun 2024
Identifier
10.71829/cei.cp.4
Certainty
Not rated
Cycle
2023 Q2
Window
28 Apr 2023 – 28 May 2023
Status
Closed
Submissions
5

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-RP-HPLC-PURI/005Dr Wilhelmina QuaresmaNothing in the standard addresses transfer of the method between laboratoriesAccepted in part
DRAFT-RP-HPLC-PURI/001Dr Quentin ZimmerthalThe standard should require documented operator competenceNot accepted
DRAFT-RP-HPLC-PURI/002Brigitta Grünbaum-SowandeThe same concept is given three different names in one documentAccepted
DRAFT-RP-HPLC-PURI/004Dr Theodora TrelawneyThe document set should be published in translationNot accepted
DRAFT-RP-HPLC-PURI/003Dr Eamon Sandringham-Adu industryThe additional determinations required would materially increase release testing costAccepted in part
5 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted1The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part2Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment0The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted2The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. Nothing in the standard addresses transfer of the method between laboratories — arising from DRAFT-RP-HPLC-PURI/005. The standard now states the maximum difference between laboratories analysing the same sample at which results are treated as agreeing, and requires that a comparison across laboratories state whether that criterion was met.
  2. The same concept is given three different names in one document — arising from DRAFT-RP-HPLC-PURI/002. A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.
  3. The additional determinations required would materially increase release testing cost — arising from DRAFT-RP-HPLC-PURI/003. One of the two determinations is now required only where the stated risk factor is present, with the factor defined in the scope, and the other is retained as a universal requirement with the reasoning stated. The submission is identified as an industry…

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.